|Free Dividend Report|
|Stock Splits Calendar|
|BEAM Stock Split History|
|Preferred Stock Newsletter|
|BEAM Options Chain|
|Stock Message Boards|
Beam Therapeutics (BEAM) has 1 split in our BEAM split history database. The split for BEAM took place on December 04, 1995. This was a 3 for 2 split, meaning for each 2 shares of BEAM owned pre-split, the shareholder now owned 3 shares. For example, a 1000 share position pre-split, became a 1500 share position following the split.
When a company such as Beam Therapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the BEAM split history from start to finish, an original position size of 1000 shares would have turned into 1500 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Beam Therapeutics shares, starting with a $10,000 purchase of BEAM, presented on a split-history-adjusted basis factoring in the complete BEAM split history.
Growth of $10,000.00
With Dividends Reinvested
|Average Annual Total Return:||6.27%|
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||6.12%|
|About Beam Therapeutics|
|Beam Therapeutics is a biotechnology company. Within its ex vivo platform, Co. has identified three development candidates. BEAM-101 reproduces single base changes seen in individuals with Hereditary Persistence of Fetal Hemoglobin to potentially protect them from the effects of mutations causing sickle cell disease or beta thalassemia. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. According to our BEAM split history records, Beam Therapeutics has had 1 split.|
|BEAM Split History Table|
|12/04/1995||3 for 2|
|Consumer Stock Splits|
|BEAM is categorized under the Consumer sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: BEAM shares outstanding history